Health Care • Biotechnology: Pharmaceutical Preparations
$20.86 ▲ +0.29
(+1.41%)
MKT CAP: $424.7M • VOL: 198.8K
52W L $19 52W H $40
ASMB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $72.3M | $28.5M | $0 |
| YoY Revenue Growth % | +153.5% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$12.1M | -$45.4M | -$64.6M |
| Operating Margin % | -16.8% | -80.0% | — |
| Net Income (GAAP) | -$6.1M | -$40.2M | -$61.2M |
| EBITDA (Normalized) | -$12.1M | -$45.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$41.1M | -$51.1M | $22.7M |
| Capital Expenditures (CapEx) | $66.0K | $28.0K | — |
| Free Cash Flow (FCF) | -$41.2M | -$51.1M | $22.7M |
| FCF Margin % | -56.9% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -6.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $58.5M | $38.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $206.8M | $33.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ASMB.